Kuros Biosciences was granted FDA 510(k) clearance to market MagnetOs Putty as a standalone bone graft in the extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft extender in posterolateral spine.
MagnetOs was previously cleared in the U.S. in a granule format under its manufacturer, Xpand Biotechnology, which was acquired by Kuros in 1Q17. Kuros intends to expand into other orthopaedic applications, such as reconstructive surgery.
Source: Kuros Biosciences
Kuros Biosciences was granted FDA 510(k) clearance to market MagnetOs Putty as a standalone bone graft in the extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft extender in posterolateral spine.
MagnetOs was previously cleared in the U.S. in a granule format...
Kuros Biosciences was granted FDA 510(k) clearance to market MagnetOs Putty as a standalone bone graft in the extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft extender in posterolateral spine.
MagnetOs was previously cleared in the U.S. in a granule format under its manufacturer, Xpand Biotechnology, which was acquired by Kuros in 1Q17. Kuros intends to expand into other orthopaedic applications, such as reconstructive surgery.
Source: Kuros Biosciences
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.